Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$4.20
-$0.15(-4.02%)
At close: 4:00 PM EDT
$4.20
-$0.15(-4.02%)
Day’s Range― - ―
52-Week Range$2.00 - $11.88
Previous Close$3.5
Volume71.67K
Average Volume (3M)78.78K
Market Cap
$43.68M
Enterprise Value$4.72M
Total Cash (Recent Filing)$93.54M
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding23,804,981
10 Day Avg. Volume75,100
30 Day Avg. Volume78,783
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-235.85
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$15.50Price Target Upside269.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits interest and refinancing pressure while preserving financial flexibility relative to a more heavily indebted biotech. This gives Kalaris greater capacity to direct available capital toward clinical development, although it does not eliminate the need for future funding.
Encouraging Early Clinical DataPositive early TH103 findings could support differentiation in ophthalmic diseases if they translate into later-stage efficacy and safety. Robust BCVA and OCT signals, together with low plasma exposure, may improve the program’s partnership and development prospects over the next several quarters.
Strengthened Financial LeadershipAdding a CFO with biotech equity research and capital-markets experience may strengthen financing preparation, investor communication, and strategic transaction readiness. Interim accounting coverage also supports reporting continuity during the broader senior finance leadership transition.
Bears Say
Pre-revenue Business ModelKalaris has no commercial revenue base to offset research and operating costs, leaving its financial outlook dependent on clinical progress and external financing. Until a candidate is successfully commercialized or partnered, earnings visibility and self-funded growth capacity remain limited.
Persistent Cash BurnSustained negative operating and free cash flow requires Kalaris to keep funding development through its available resources or additional financing. Continued burn can reduce strategic flexibility and makes successful clinical execution increasingly important to preserving long-term operating capacity.
Shrinking Equity BaseThe substantial decline in shareholders’ equity reflects the cumulative impact of ongoing losses and cash consumption. A smaller capital base can constrain the company’s ability to absorb setbacks, fund multiple development priorities, or sustain operations without further capital raising.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.00 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $43.68M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 29 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.495 by $0.015.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 23,804,981 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.495. Following the earnings report the stock price went up 0.761%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (269.05% Upside)
$15.50 (269.05% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.24%
12-Months-Change
Fundamentals
Return on Equity
-71.71%
Trailing 12-Months
Asset Growth
7.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kalaris Therapeutics
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
KLRS Stock 12 Month Forecast
Average Price Target
$15.50
▲(269.05% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
54.44% Insiders
1.98% Mutual Funds
4.37% Other Institutional Investors
38.07% Public Companies and
Individual Investors